Navigation Links
Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
Date:9/4/2013

opment and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca for the sales and marketing of VIMOVO®; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2013. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.Contact:Sanofi USCarrie Brown(908) 981 6486Carrie.brown@sanofi.com POZEN Inc.Bill Hodges

Stephanie BonestellChief Financial Officer

Manager, Investor Relations and Public Relations(919) 913 1030

(919) 913 1030

SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
2. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
3. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
4. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
8. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
9. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. NextBio Announces Translational Medicine Partnership with Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 China Nepstar Chain Drugstore ... a leading retail drugstore chain in China based ... announced its unaudited financial results for the fourth ... Financial HighlightsFor the quarter ended December 31, 2014: ... compared to the fourth quarter of 2013 ...
(Date:3/27/2015)... 2015 Across the global healthcare landscape, the ... clinical development, market education, and regulatory compliance. As emerging ... function is expected to increase in prominence and follow ... According to research by benchmarking firm, Best Practices, LLC, ... to Medical Affairs. Among companies in India ...
(Date:3/27/2015)... Levi & Korsinsky announces it has commenced ... ) concerning possible violations of federal securities laws. The ... connection with its study of the drug OHR-102. To ... contact Joseph E. Levi, Esq. either via ... (212) 363-7500, toll-free: (877) 363-5972. Levi & ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 11China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 12China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 13China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 14China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 15Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... SANTA BARBARA, Calif., June 20, 2011 Inogen has ... (MDEA) for the Inogen One Portable Oxygen Concentrator.  The ... program that exclusively recognizes contributions and advances in the ... One, developed by Goleta, California based Inogen, Inc. is ...
... 2011 The U.S. Food and Drug Administration today ... and approval of an artificial pancreas system to treat ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Type ... pancreas produces little or no insulin, a hormone needed ...
Cached Medicine Technology:Inogen One Wins Gold Medical Design Excellence Award 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3
(Date:3/30/2015)... This report studies the global ... forecast period of 2014 to 2019. This market ... 6.5% from 2014 to 2019. , Further Inquiry ... the global pharmacovigilance and drug safety software market ... basis of functionality, namely, adverse event reporting software, ...
(Date:3/30/2015)... Dr. Shahdad Arami is ... will receive $200 off their Invisalign treatment. Many people ... wearing a mouthful of metal. Invisalign offers an alternative. ... braces is effective for straightening teeth but has no ... their oral appearance. The Invisalign system allows both teenagers ...
(Date:3/30/2015)... Angeles, CA (PRWEB) March 30, 2015 ... traditional blue polo for yellow to inspire courage in ... suffers from Severe Combined Immunodeficiency (SCID). SCID causes affected ... bone marrow transplant is needed to allow the development ... second transplant last Friday, created a video with his ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a ... opening/closing and for reuse. Consumers simply twist the cup, turn ... Yorkers, professionals, and basically anyone can now enjoy a ... back socially or pair with meals at work, home, or ... wine and that means Napa Wine grapes undergo the ...
(Date:3/30/2015)... TX (PRWEB) March 30, 2015 ... been Drummond Certified™ in the second AS4 test ... Inc., the trusted leader in interoperability software testing. ... Oracle and Software AG participated in this vendor-neutral ... represents the first AS4 interoperability certifications for IBM, ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... Reporter , THURSDAY, June 2 (HealthDay News) -- New ... part of the plan, don,t appear to harm the ... clear low-carb is effective for weight loss," said study ... exercise physiology at the Johns Hopkins University School of ...
... liver diseases such as hepatitis C (HCV) are typically ... disease progression. For patients who question whether less invasive ... consider. Elastography and serum markers are two such diagnostic ... issue of Hepatology , a journal of the ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay ... more likely to suffer from anxiety, loneliness, low self-esteem ... and math test scores, new research suggests. Children ... during the potentially disruptive period before their parents divorce, ...
... study from North Carolina State University shows that talking about ... transgender community. The finding may help efforts to promote safer ... and also sheds light on broader questions related to safer ... is the fact that we,re seeing evidence of devastatingly high ...
... 2, 2011 In a multicenter clinical trial, ... higher doses of stereotactic radiation therapy requiring fewer ... low-to-intermediate-risk prostate cancer. Results of the trial, ... , showed that stereotactic body radiation therapy (SBRT), ...
... of the most lethal cancers, advanced melanoma, has improved response ... immunotherapy drug Interleukin-2, according to research led by scientists from ... University Health Goshen Center for Cancer Care. The ... of Medicine , mark the first vaccine study in the ...
Cached Medicine News:Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3Health News:Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 3Health News:Safer sex: Study examines sexual communication in transgender community 2Health News:Higher doses of radiation in fewer treatments proved safe, effective for low-risk prostate cancer 2Health News:Therapeutic melanoma vaccine improves response rate, progression-free survival 2Health News:Therapeutic melanoma vaccine improves response rate, progression-free survival 3
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: